Literature DB >> 6842692

Topical beta-aminopropionitrile in the treatment of Peyronie's disease.

M Gelbard, A Lindner, M Chvapil, J Kaufman.   

Abstract

We treated 9 patients with Peyronie's disease for 1 to 8 years in duration with a 4-week course of beta-aminopropionitrile free base as the pure liquid. The drug was applied topically to the plaques twice daily. Patients were followed with ultrasound imaging of the plaques and saline inflations of the corpora cavernosa with photographic documentation of the deformity. No significant adverse effect was noted. Three patients experienced a subjective response but did not demonstrate objective change on the aforementioned studies. It was concluded that topical beta-aminopropionitrile was not effective in reversing the deformity of Peyronie's disease. Further investigation into specific anti-collagen drugs for the treatment of this condition may be warranted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6842692     DOI: 10.1016/s0022-5347(17)52339-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Treatment of Peyronie's disease: 2012 update.

Authors:  Ege Can Serefoglu; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 2.  Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence.

Authors:  Elizabeth J Traore; William Wang; Faysal A Yafi; Wayne J G Hellstrom
Journal:  Ther Adv Urol       Date:  2016-03-22

3.  Pathogenesis, diagnosis and therapy of induratio penis plastica (IPP).

Authors:  H J Schneider; E W Rugendorff; C Röhrborn
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

Review 4.  Pharmacological Management of Peyronie's Disease.

Authors:  Landon W Trost; Serap Gur; Wayne J G Hellstrom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Current and emerging treatment options for Peyronie's disease.

Authors:  Ahmet Gokce; Julie C Wang; Mary K Powers; Wayne Jg Hellstrom
Journal:  Res Rep Urol       Date:  2013-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.